1 / 13

Audit in VTE prevention

Audit in VTE prevention. Peter Davies Senior Pharmacist. Drivers for audit. Venous thromboembolic prevention is a DH patient safety priority NICE clinical guideline venous thromboembolism reducing the risk CQUIN The NHS standard contract for acute services and VTE prevention.

dagan
Download Presentation

Audit in VTE prevention

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Audit in VTE prevention Peter Davies Senior Pharmacist

  2. Drivers for audit • Venous thromboembolic prevention is a DH patient safety priority • NICE clinical guideline venous thromboembolism reducing the risk • CQUIN • The NHS standard contract for acute services and VTE prevention

  3. Audit of VTE currently being undertaken by the Trust • VTE risk assessment audit • Clinical incident/Pharmacy intervention monitoring • Healthcare record audit • Root cause analysis of hospital acquired thrombosis • Rivaroxaban use in elective THR and TKR

  4. VTE risk assessment • Audit data since June 2008 • Data collected from the front of the drug administration and record chart • 3 monthly data until May 2010 now monthly • CQUIN requirements

  5. VTE risk assessment audit results

  6. Clinical incident and Pharmacy intervention reporting • Reporting forms adapted to include fields to record incidents and interventions relating to VTE prevention and prophylaxis • Report generated by clinical risk and sent monthly to the thrombosis committee

  7. Healthcare records audit • Data provided by individual wards • Audit of 5 sets of healthcare records • Record data on whether risk assessment and thromboprophylaxis is appropriate on an electronic data collection form • Data collated by clinical audit and forwarded to the Thrombosis committee

  8. Root cause analysis of hospital acquired thrombosis • Hospital acquired thrombosis detected by DVT/Anticoagulant clinic Coding Diagnostics Autopsies • Subjected to a root cause analysis • Reviewed by the Thrombosis committee

  9. Rivaroxabanthromboprophylaxis following elective THR and TKR • For elective Primary THR or TKR • First dose 30 hours post surgery • 14 days for TKR and 35 days for THR • Contra-indicated e-GFR <30ml/min • Not used if on long term anticoagulant

  10. Number of patients prescribed dalteparin in place of rivaroxaban

More Related